Company / Gross Margin
NovaBay Pharmaceuticals, Inc. Gross Margin History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
84.7%
FY2017
5-year range
-
FY2015-FY2017
Trend
+6.9%
vs FY2016
Sector context
#7 of 26
Health Care
What the data says
At 84.7%, NovaBay Pharmaceuticals, Inc.'s gross margin ranks #7 of 26 in the Health Care sector. Improved from 71.2% to 84.7% over the past 2 years.
Based on SEC 10-K filings.
84.7% in FY2017. Top quartile in the Health Care sector.
Improved from 71.2% to 84.7% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#7 of 26 in Health CareTop 27% of 26This company 84.7% Sector average 61.9%
▼
+36.9% above sector average
Key checks
Key Insights
- In FY2017, gross margin increased 6.9% year-over-year.
- Currently 22.8pp above the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | 84.7% | +6.9% |
| FY2016 | 79.3% | +11.3% |
| FY2015 | 71.2% | -53.6% |
As of FY2017 · SEC 10-K · Updated Feb 28, 2026